Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.J&J’s drug found effective in preventing venous thromboembolism
Data from the Record1 study show that rivaroxaban demonstrated a 70% relative risk reduction (RRR) in total venous thromboembolism (VTE) when compared with enoxaparin, and an 88% RRR
Data from the Record1 study show that rivaroxaban demonstrated a 70% relative risk reduction (RRR) in total venous thromboembolism (VTE) when compared with enoxaparin, and an 88% RRR
This 103 subject trial is the first randomized, double-blind, placebo- controlled clinical trial studying vigabatrin’s effectiveness in treating cocaine addiction. These data show that a statistically significantly greater
The initiation of the expanded access program will not impact enrolment in the company’s Phase III clinical trial as only patients who are not eligible to participate in
Under the terms of the transaction, Discovery Labs will sell 10 million shares of its common stock to a select group of institutional investors at a purchase price
AP24534 demonstrated potent inhibition of selected additional kinase targets – the receptors for vascular endothelial growth factors (VEGFR), fibroblast growth factors (FGFR) and angiopoietin (Tie2) that control angiogenesis,
As induction therapy prior to stem cell transplantation (SCT), the Velcade, thalidomide and dexamethasone (VcTD) arm demonstrated a complete remission (CR, including immunofixation positive and negative) rate of
SPI-452 is said to be designed to improve the exposure of co-administered HIV medications thereby providing more efficacious, less toxic and more user-friendly drug regimens. Sequoia’s first IND
LGD-4665 showed impressive activity following single and multiple doses with an increase in mean maximum platelet counts of 58% with a single dose administration of 120 mg and
Under the terms of the settlement agreement, the companies agree that Yeda is the sole owner of the 6,217,866 (866) patent in the US, and Yeda and Sanofi-Aventis
Results from the Sonama-2 trial show that alfimeprase restored catheter function in patients with occluded catheters within 15 minutes in 34.3% of patients in the alfimeprase group versus